Development and use of methylnaltrexone, a peripherally acting opioid antagonist, to treat side effects related to opioid use

Drug Development Research

Volumn 70, Issue 6, 2009, Pages 403-416

  Yuan, Chun Su ^a   Foss, Joseph F ^b   Williams, Wade A ^c   Moss, Jonathan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Constipation; Methylnaltrexone; Peripheral opioid antagonist; Relistor

Indexed keywords

17 METHYLNALTREXONE; BEVACIZUMAB; DELTA OPIATE RECEPTOR; FLUOROURACIL; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MU OPIATE RECEPTOR; OPIATE; PARACETAMOL; PLACEBO; RELISTOR; RITONAVIR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANALGESIA; ANGIOGENESIS; ANOREXIA; AREA UNDER THE CURVE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSPHORIA; GASTROINTESTINAL SYMPTOM; HUMAN; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OPIOID INDUCED EMESIS; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; STOMACH EMPTYING; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VITAL SIGN;

EID: 70349269258     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20318     Document Type: Review

References (88)

1. Abraham JL. 2000. A physician's guide to pain and symptom management in cancer patients. Baltimore: Johns Hopkins University Press.
2. Adcock JJ, Schneider C, Smith TW. 1988. Effects of codeine, morphine and a novel opioid pentapeptide BW443C, on cough, nociception and ventilation in the unanaesthetized guinea-pig. Br J Pharmacol 93:93-100. (Pubitemid 18105594)
3. Amin HM, Sopchak AM, Foss JF, Esposito BF, Roizen MF, Camporesi EM. 1994. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg 78:701-705.
4. Andrews PL, Wood KL. 1988. Vagally mediated gastric motor and emetic reflexes evoked by stimulation of the antral mucosa in anaesthetized ferrets. J Physiol 395:1-16.
5. Aparasu R, McCoy RA, Weber C, Mair D, Parasuraman TV. 1999. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage 18:280-288. (Pubitemid 29469706)
6. Aung HH, Mehendale SR, Xie JT, Moss J, Yuan CS. 2004. Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci 74:2685-2691. (Pubitemid 38388495)
7. Bauer AJ, Boeckxstaens GE. 2004. Mechanisms of postoperative ileus. Neurogastroenterol Motil 16(Suppl 2):54-60.
8. Bhandari P, Bingham S, Andrews PL. 1992. The neuropharmacology of loperamide-induced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 31:735-742.
9. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. 2008. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109:180-187.
10. Bitar KN, Makhlouf GM. 1985. Selective presence of opiate receptors on intestinal circular muscle cells. Life Sci 37:1545-1550. (Pubitemid 15239542)
11. Blonsky R, Michna E, Schulman S, Tzanis E, Manley A, Zhang H, Randazzo B. 2009. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain. Am Pain Soc:Abstr 308.
12. Brown DR, Goldberg LI. 1985. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24:181-191.
13. Cadet P. 2004. Mu opiate receptor subtypes. Med Sci Monit 10:MS28-MS32.
14. Campora E, Merlini L, Pace M, Bruzzone M, Luzzani M, Gottlieb A, Rosso R. 1991. The incidence of narcotic-induced emesis. J Pain Symptom Manage 6:428-430.
15. Chakravarty NK, Matallana A, Jensen R, Borison HL. 1956. Central effects of antitussive drugs on cough and respiration. J Pharmacol Exp Ther 117:127-135.
16. Choi YS, Billings JA. 2002. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 24:71-90.
17. Dhanabal M, Jeffers M, Larochelle WJ. 2005. Anti-angiogenic therapy as a cancer treatment paradigm. Curr Med Chem Anticancer Agents 5:115-130. (Pubitemid 40347985)
18. Eisenstein TK, Hilburger ME. 1998. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 83:36-44.
19. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. 2006. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105:660-664.
20. Ferritti P, Tavani A, Manara L. 1981. Inhibition of gastrointestinal transit and antiociceptive effects of morphine and FK-33-824 in rats are differently prevented by naloxone and the N-methyl quaternary analog. Res Commun Subst Abuse 2:1-11. (Pubitemid 11118572)
21. Foss JF, Bass AS, Goldberg LI. 1993. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol 33:747-751.
22. Foss JF, Orelind E, Goldberg LI. 1996. Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs. Life Sci 59:PL235-PL238. (Pubitemid 26322925)
23. Foss JF, O'Connor MF, Yuan CS, Murphy M, Moss J, Roizen MF. 1997. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol 37:25-30. (Pubitemid 27131551)
24. Foss JF, Yuan CS, Roizen MF, Goldberg LI. 1998. Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol 42:287-291.
25. Gmerek DE, Cowan A, Woods JH. 1986. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 236:8-13. (Pubitemid 16186117)
26. Goldberg LI, Merz H, Stockhaus K. 1979. Quaternary derivatives of noroxymorphone which relieve intestinal immobility, A61K 41/485 Edition. Edited by USPTO. United States, Boehringer Ingelheim GmbH.
27. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP. 2002. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62:4491-4498. (Pubitemid 34827313)
28. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. 2002. Naloxone treatment for irritable bowel syndrome - a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 16:1649-1654. (Pubitemid 35052741)
29. Ho WZ, Guo CJ, Yuan CS, Douglas SD, Moss J. 2003. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 307:1158-1162. (Pubitemid 37494237)
30. Improta G, Broccardo M. 1994. Effect of selective mu 1, mu 2 and delta 2 opioid receptor agonists on gastric functions in the rat. Neuropharmacology 33:977-981. (Pubitemid 2138985)
31. Isayeva T, Kumar S, Ponnazhagan S. 2004. Anti-angiogenic gene therapy for cancer (review). Int J Oncol 25:335-343.
32. Kaczor A, Matosiuk D. 2002. Non-peptide opioid receptor ligands - recent advances. Part I. Agonists. Curr Med Chem 9:1567-1589.
33. Kehlet H. 2000. Endogenous morphine - another component and biological modifier of the response to surgical injury? Acta Anaesthesiol Scand 44:1167-1168.
34. Kieffer BL, Gaveriaux-Ruff C. 2002. Exploring the opioid system by gene knockout. Prog Neurobiol 66:285-306. (Pubitemid 34518287)
35. Kotake AN, Kuwahara SK, Burton E, McCoy CE, Goldberg LI. 1989. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 19:1247-1254. (Pubitemid 19275638)
36. Kreek MJ, Schaefer RA, Hahn EF, Fishman J. 1983. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1:261-262. (Pubitemid 13184278)
37. Kurz A, Sessler DI. 2003. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649-671. (Pubitemid 36408072)
38. Levy JH, Brister NW, Shearin A, Ziegler J, Hug Jr CC, Adelson DM, Walker BF. 1989. Wheal and flare responses to opioids in humans. Anesthesiology 70:756-760. (Pubitemid 19129029)
39. Ling GS, Paul D, Simantov R, Pasternak GW. 1989. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci 45:1627-1636. (Pubitemid 19275490)
40. Manara L, Bianchetti A. 1985. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 25:249-273. (Pubitemid 15090982)
41. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. 1995. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 700:89-98.
42. Mehendale SR, Yuan CS. 2006. Opioid-induced gastrointestinal dysfunction. Dig Dis 24:105-112.
43. Mehendale SR, Yuan CS. 2008. Clinical pharmacology of opioids: basic pharmacology. In: Sykes N, Bennett M, Yuan CS, editors. Cancer pain. 2nd edition. London: Arnold. p 151-167.
44. Murphy DB, Sutton JA, Prescott LF, Murphy MB. 1997. Opioidinduced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87:765-770.
45. Osinski J, Wang A, Wu JA, Foss JF, Yuan CS. 2002. Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. J Chromatogr B Anal Technol Biomed Life Sci 780:251-259. (Pubitemid 35223560)
46. Ouyang A, Vos P, Cohen S. 1988. Sites of action of mu-, kappa- and sigma-opiate receptor agonists at the feline ileocecal sphincter. Am J Physiol 254:G224-G231. (Pubitemid 18077264)
47. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. 2005. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 133:209-220. (Pubitemid 40694171)
48. Pappagallo M. 2001. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S-18S. (Pubitemid 34072942)
49. Pasternak GW. 2001. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22:67-70.
50. Pasternak GW. 2005. Molecular biology of opioid analgesia. J Pain Symptom Manage 29:S2-S9.
51. Petersen TK, Husted SE, Rybro L, Schurizek BA, Wernberg M. 1982. Urinary retention during i.m. and extradural morphine analgesia. Br J Anaesth 54:1175-1178.
52. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ. 2008. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35:458-468. (Pubitemid 351601995)
53. Read NW, Al-Janabi MN, Bates TE, Holgate AM, Cann PA, Kinsman RI, McFarlane A, Brown C. 1985. Interpretation of the breath hydrogen profile obtained after ingesting a solid meal containing unabsorbable carbohydrate. Gut 26:834-842.
54. Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R. 2007. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 82:48-53. (Pubitemid 46944195)
55. Russell J, Bass P, Goldberg LI, Schuster CR, Merz H. 1982. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78:255-261. (Pubitemid 12190685)
56. Singleton PA, Garcia JG, Moss J. 2008. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 7:1669-1679.
57. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. 2006. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 72:3-11. (Pubitemid 44118390)
58. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. 2007. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 37:222-231. (Pubitemid 47255005)
59. Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N and others. 2009. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 7:39-46.
60. Sullivan SN. 1984. The pharmacologic effects of naloxone and an enkephalin analogue on human upper gastrointestinal motility and secretion. In: Fraioli F, Isidori A, Mazzetti M, editors. Opioid peptides in the periphery. New York: Elsevier Science. p 213-224.
61. Tan-No K, Niijima F, Nakagawasai O, Sato T, Satoh S, Tadano T. 2003. Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur J Pharm Sci 20:357-363. (Pubitemid 37338542)
62. Thomas J, Portenoy RK, Moehl M, Von Gunten C, Thielemann P, Stambler N, Tran D, Galasso F, Israel R. 2003. A phase II randomized dose-finding trail of methylnaltrexone for the relief of opioid-induced constipation in hospice patients. Proc Am Soc Clin Oncol 22:2933.
63. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ. 2008. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358:2332-2343. (Pubitemid 351749157)
64. Thompson AR, Ray JB. 2003. The importance of opioid tolerance: a therapeutic paradox. J Am Coll Surg 196:321-324.
65. Uhl GR, Sora I, Wang Z. 1999. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96:7752-7755. (Pubitemid 29328353)
66. Viscusi E, Rathmell J, Fichera A, Gan TJ, Israel RJ. 2005. A double-blind, randomized, placebo-controlled trial of methylnaltrexone for post-operative bowel dysfunction in segmental colectomy patients. Proc Am Soc Anesth 1630.
67. Walker MJ, Le AD, Poulos CX, Cappell H. 1991. Role of central versus peripheral opioid receptors in analgesia induced by repeated administration of opioid antagonists. Psychopharmacology (Berl) 104:164-166.
68. Wei G, Moss J, Yuan CS. 2003. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol 65:1761-1766.
69. Woo M, O'Connor M, Yuan CS, Moss J. 2008. Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg 107:1965-1967.
70. Woods JH, Medzihradsky F, Smith CB, Young AM, Swain HH. 1981. Annual report: evaluation of new compounds for opioid activity (1980). NIDA Res Monog 34:327-366. (Pubitemid 12221665)
71. Yuan CS. 1996. Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat. Eur J Pharmacol 314:27-32.
72. Yuan CS. 2007. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 41:984-993.
73. Yuan CS, Foss JF. 1999. Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology 38:425-432.
74. Yuan CS, Foss JF. 2000. Oral methylnaltrexone for opioid-induced constipation. JAMA 284:1383-1384.
75. Yuan CS, Foss JF, Moss J. 1995. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol 276:107-111.
76. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. 1996. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59:469-475. (Pubitemid 26151630)
77. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. 1997. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 61:467-475. (Pubitemid 27195949)
78. Yuan CS, Foss JF, O'Connor M, Roizen MF, Moss J. 1998a. Effects of low-dose morphine on gastric emptying in healthy volunteers. J Clin Pharmacol 38:1017-1020. (Pubitemid 28524448)
79. Yuan CS, Karrison T, Wu JA, Lowell TK, Lynch JP, Foss JF. 1998b. Dose-related effects of oral acetaminophen on cold-induced pain: a double-blind, randomized, placebo-controlled trial. Clin Pharmacol Ther 63:379-383. (Pubitemid 28182235)
80. Yuan CS, Foss JF, O'Connor M, Moss J, Roizen MF. 1998c. Gut motility and transit changes in patients receiving long-term methadone maintenance. J Clin Pharmacol 38:931-935.
81. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. 1998d. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 52:161-165.
82. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. 1999. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 83:631-635.
83. Yuan CS, Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, Moss J. 2000a. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 67:398-404. (Pubitemid 30246817)
84. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF. 2000b. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283:367-372. (Pubitemid 30051755)
85. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J. 2002. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300:118-123. (Pubitemid 34028517)
86. Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, Israel RJ, Moss J. 2005. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45:538-546. (Pubitemid 40562944)
87. Yuan CS, Wang CZ, Mehendale SR, Aung HH, Israel RJ. 2008. Methylnaltrexone (MNTX) attenuated protease inhibitor-induced nausea and vomiting in a rat pica model. Anesth Analg 106:S192.
88. Zeil K, Freter K. 1963. Quaternary salts of normorphine and its acylated derivatives. Edited by USPTO, C. H. Boehringer Sohn.